Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 4/2018

23.02.2017 | Übersichten

Crystal arthritides – gout and calcium pyrophosphate arthritis

Part 1: Epidemiology and pathophysiology

verfasst von: Dr. med. S. Schlee, L. C. Bollheimer, T. Bertsch, C. C. Sieber, P. Härle

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Gout and calcium pyrophosphate deposition disease (CPPD, pseudogout) are still the most frequent inflammatory arthritides in multimorbid elderly patients. Gout and CPPD are different diseases and based on different pathophysiological principles. Gout is closely associated with the metabolic syndrome and is an independent risk factor for cardiovascular mortality. The prevalence of asymptomatic hyperuricemia is estimated to be 10–20% of adults in industrial nations and prevalence is strongly associated with age. More than 7% of persons aged over 65 years suffer from clinically manifest gout. The underlying pathophysiological principle is an imbalance between the formation and elimination of uric acid. The degradation of the purine bases adenine and guanosine to uric acid is catalysed by xanthine oxidase and genetic polymorphisms and mutations play an important role in absorption and excretion processes. Furthermore, carrier proteins, such as URAT-1 or OAT-4 also have an influence on these processes. An imbalance of the physiological processes results in the solubility product being exceeded, which in consequence leads to crystallization of urate. This induces a cascade of massive inflammatory reactions at the molecular and cellular level with the activation of cytokines. The inflammatory process can be stopped by neutrophil extracellular traps (NETs) that modulate aggregation and degradation of chemokines and cytokines and partitioning of crystallized urate against immune cells. Calcium pyrophosphate dehydrate (CPP) crystals are formed in the cartilage and CPP deposition can be found in 30% of people aged over 80 years. Inorganic pyrophosphate (PPi) is synthesized in chondrocytes and plays an important part in the formation of calcium pyrophosphate crystals. The degradation is catalyzed by inorganic pyrophosphatases. If there is dysregulation of this homeostasis more PPi is produced, which ultimately contributes to the formation of the CPP crystals.
Literatur
1.
Zurück zum Zitat Bhansing KJ, Van Bon L, Janssen M et al (2010) Gout: A clinical syndrome illustrated and discussed. Neth J Med 68:352–359PubMed Bhansing KJ, Van Bon L, Janssen M et al (2010) Gout: A clinical syndrome illustrated and discussed. Neth J Med 68:352–359PubMed
2.
Zurück zum Zitat Bhole V, De Vera M, Rahman MM et al (2010) Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum 62:1069–1076CrossRefPubMed Bhole V, De Vera M, Rahman MM et al (2010) Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum 62:1069–1076CrossRefPubMed
5.
Zurück zum Zitat Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277–1281CrossRefPubMed Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277–1281CrossRefPubMed
7.
Zurück zum Zitat Choi HK, Mount DB, Reginato AM et al (2005) Pathogenesis of gout. Ann Intern Med 143:499–516CrossRefPubMed Choi HK, Mount DB, Reginato AM et al (2005) Pathogenesis of gout. Ann Intern Med 143:499–516CrossRefPubMed
9.
Zurück zum Zitat Chong CR, Chan WP, Nguyen TH et al (2014) Thioredoxin-interacting protein: Pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther 28:347–360CrossRefPubMed Chong CR, Chan WP, Nguyen TH et al (2014) Thioredoxin-interacting protein: Pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther 28:347–360CrossRefPubMed
10.
Zurück zum Zitat Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 4:701–712CrossRefPubMed Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 4:701–712CrossRefPubMed
11.
Zurück zum Zitat Dalbeth NHD (2006) Pathophysiology of crystal-induced arthritis. In: Wortmann RLSHJ, Becker MA, Ryan LM (eds) Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes. Taylor & Francis Group, New York, p 239CrossRef Dalbeth NHD (2006) Pathophysiology of crystal-induced arthritis. In: Wortmann RLSHJ, Becker MA, Ryan LM (eds) Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes. Taylor & Francis Group, New York, p 239CrossRef
12.
Zurück zum Zitat Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 75(Suppl 5):13–16CrossRef Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 75(Suppl 5):13–16CrossRef
13.
Zurück zum Zitat Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 32:804–812CrossRefPubMed Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 32:804–812CrossRefPubMed
14.
Zurück zum Zitat Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300:924–932CrossRefPubMedPubMedCentral Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300:924–932CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hernan MA, Chen H, Schwarzschild MA et al (2003) Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol 54:170–175CrossRefPubMed Hernan MA, Chen H, Schwarzschild MA et al (2003) Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol 54:170–175CrossRefPubMed
16.
Zurück zum Zitat Ho AM, Johnson MD, Kingsley DM (2000) Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289:265–270CrossRefPubMed Ho AM, Johnson MD, Kingsley DM (2000) Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289:265–270CrossRefPubMed
17.
Zurück zum Zitat Kim SY, Guevara JP, Kim KM et al (2010) Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62:170–180 Kim SY, Guevara JP, Kim KM et al (2010) Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62:170–180
18.
19.
Zurück zum Zitat Luk AJ, Levin GP, Moore EE et al (2009) Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 48:804–806CrossRef Luk AJ, Levin GP, Moore EE et al (2009) Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 48:804–806CrossRef
20.
Zurück zum Zitat Marson PPG (2011) Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo 63:199–206 Marson PPG (2011) Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo 63:199–206
21.
Zurück zum Zitat Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed
22.
Zurück zum Zitat Matsuo H, Chiba T, Nagamori S et al (2008) Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83:744–751CrossRefPubMedPubMedCentral Matsuo H, Chiba T, Nagamori S et al (2008) Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83:744–751CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Matsuo H, Nakayama A, Sakiyama M et al (2014) ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep 4:3755CrossRefPubMedPubMedCentral Matsuo H, Nakayama A, Sakiyama M et al (2014) ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep 4:3755CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Matsuo H, Takada T, Ichida K et al (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. Sci Transl Med 1:5ra11CrossRefPubMed Matsuo H, Takada T, Ichida K et al (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. Sci Transl Med 1:5ra11CrossRefPubMed
25.
Zurück zum Zitat Mikuls TR, Farrar JT, Bilker WB et al (2005) Gout epidemiology: Results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMedPubMedCentral Mikuls TR, Farrar JT, Bilker WB et al (2005) Gout epidemiology: Results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Mitroulis I, Kambas K, Chrysanthopoulou A et al (2011) Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLOS ONE 6:e29318CrossRefPubMedPubMedCentral Mitroulis I, Kambas K, Chrysanthopoulou A et al (2011) Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLOS ONE 6:e29318CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Netea MG, Brown GD, Kullberg BJ et al (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6:67–78CrossRefPubMed Netea MG, Brown GD, Kullberg BJ et al (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6:67–78CrossRefPubMed
29.
Zurück zum Zitat Oliviero F, Scanu A, Punzi L (2011) Metabolism of crystals within the joint. Reumatismo 63:221–229 Oliviero F, Scanu A, Punzi L (2011) Metabolism of crystals within the joint. Reumatismo 63:221–229
30.
Zurück zum Zitat Palacios N, Gao X, O’reilly E et al (2012) Alcohol and risk of Parkinson’s disease in a large, prospective cohort of men and women. Mov Disord 27:980–987CrossRefPubMedPubMedCentral Palacios N, Gao X, O’reilly E et al (2012) Alcohol and risk of Parkinson’s disease in a large, prospective cohort of men and women. Mov Disord 27:980–987CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Papayannopoulos V, Zychlinsky A (2009) NETs: a new strategy for using old weapons. Trends Immunol 30:513–521CrossRefPubMed Papayannopoulos V, Zychlinsky A (2009) NETs: a new strategy for using old weapons. Trends Immunol 30:513–521CrossRefPubMed
32.
Zurück zum Zitat Polekhina G, Ascher DB, Kok SF et al (2011) Crystallization and preliminary X‑ray analysis of the N‑terminal domain of human thioredoxin-interacting protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 67:613–617CrossRefPubMedPubMedCentral Polekhina G, Ascher DB, Kok SF et al (2011) Crystallization and preliminary X‑ray analysis of the N‑terminal domain of human thioredoxin-interacting protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 67:613–617CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Rosenthal AK, Gohr CM, Mitton-Fitzgerald E et al (2013) The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. Arthritis Res Ther 15:R154CrossRefPubMedPubMedCentral Rosenthal AK, Gohr CM, Mitton-Fitzgerald E et al (2013) The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. Arthritis Res Ther 15:R154CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Schauer C, Janko C, Munoz LE et al (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20:511–517CrossRefPubMed Schauer C, Janko C, Munoz LE et al (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20:511–517CrossRefPubMed
38.
Zurück zum Zitat Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907–1912CrossRefPubMed Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907–1912CrossRefPubMed
39.
Zurück zum Zitat Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521CrossRefPubMed Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521CrossRefPubMed
40.
Zurück zum Zitat So A (2007) Recent advances in the pathophysiology of hyperuricemia and gout. Rev Med Suisse 3(720):722–724 So A (2007) Recent advances in the pathophysiology of hyperuricemia and gout. Rev Med Suisse 3(720):722–724
41.
Zurück zum Zitat Tan P, Hyndman D, Liu S (2011) Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide. Ann Rheum Dis 70:187 Tan P, Hyndman D, Liu S (2011) Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide. Ann Rheum Dis 70:187
43.
Zurück zum Zitat Torres RJ, De Miguel E, Bailen R et al (2014) Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol 41:1863–1870CrossRefPubMed Torres RJ, De Miguel E, Bailen R et al (2014) Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol 41:1863–1870CrossRefPubMed
Metadaten
Titel
Crystal arthritides – gout and calcium pyrophosphate arthritis
Part 1: Epidemiology and pathophysiology
verfasst von
Dr. med. S. Schlee
L. C. Bollheimer
T. Bertsch
C. C. Sieber
P. Härle
Publikationsdatum
23.02.2017
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 4/2018
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-017-1197-3

Weitere Artikel der Ausgabe 4/2018

Zeitschrift für Gerontologie und Geriatrie 4/2018 Zur Ausgabe

Mitteilungen des BV-Geriatrie

Mitteilungen des BV-Geriatrie